全文获取类型
收费全文 | 10674篇 |
免费 | 705篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 350篇 |
妇产科学 | 328篇 |
基础医学 | 1471篇 |
口腔科学 | 342篇 |
临床医学 | 1651篇 |
内科学 | 1777篇 |
皮肤病学 | 160篇 |
神经病学 | 954篇 |
特种医学 | 191篇 |
外科学 | 935篇 |
综合类 | 108篇 |
一般理论 | 10篇 |
预防医学 | 1562篇 |
眼科学 | 149篇 |
药学 | 675篇 |
1篇 | |
中国医学 | 20篇 |
肿瘤学 | 649篇 |
出版年
2023年 | 63篇 |
2022年 | 59篇 |
2021年 | 223篇 |
2020年 | 181篇 |
2019年 | 250篇 |
2018年 | 319篇 |
2017年 | 210篇 |
2016年 | 275篇 |
2015年 | 289篇 |
2014年 | 421篇 |
2013年 | 579篇 |
2012年 | 881篇 |
2011年 | 919篇 |
2010年 | 520篇 |
2009年 | 481篇 |
2008年 | 800篇 |
2007年 | 811篇 |
2006年 | 765篇 |
2005年 | 716篇 |
2004年 | 663篇 |
2003年 | 545篇 |
2002年 | 554篇 |
2001年 | 76篇 |
2000年 | 47篇 |
1999年 | 76篇 |
1998年 | 86篇 |
1997年 | 61篇 |
1996年 | 42篇 |
1995年 | 58篇 |
1994年 | 46篇 |
1993年 | 51篇 |
1992年 | 31篇 |
1991年 | 17篇 |
1990年 | 22篇 |
1989年 | 25篇 |
1988年 | 25篇 |
1987年 | 17篇 |
1986年 | 10篇 |
1985年 | 19篇 |
1984年 | 18篇 |
1983年 | 24篇 |
1982年 | 18篇 |
1981年 | 25篇 |
1980年 | 25篇 |
1979年 | 20篇 |
1978年 | 11篇 |
1977年 | 8篇 |
1976年 | 5篇 |
1974年 | 4篇 |
1972年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
1.
2.
3.
Denise Lee Marcella D. Walker Hsin Yi Chen John A. Chabot James A. Lee Jennifer H. Kuo 《Surgery》2019,165(1):107-113
Background
Bone mineral density (BMD) has been found to improve after parathyroidectomy (PTX) in patients with primary hyperparathyroidism. There are few data on the effect of PTX on BMD in normocalcemic and normohormonal primary hyperparathyroidism.Methods
A retrospective analysis of 92 primary hyperparathyroidism patients who underwent PTX between 2004 and 2012 with pre- and post-PTX dual-energy x-ray absorptiometry was performed. Within-person changes in BMD pre- and post-PTX were analyzed using log linear mixed models, stratified by biochemical status.Results
Bone mineral density increased post-PTX in the whole cohort at the lumbar spine (+2.5%), femoral neck (+2.1%), and total hip (+1.9%) and decreased at the one-third radius (–0.9%). On comparison of BMD changes by profile, BMD increased in those with the typical profile at the lumbar spine (3.2%), femoral neck (2.9%), and total hip (2.9%) but declined at the one-third radius (–1.5%). In contrast, BMD improved only at the femoral neck (4.3%) in the normohormonal group and did not change at any site in the normocalcemic group. The typical group had a greater increase in BMD over time at the femoral neck and total hip compared with normocalcemic patients.Conclusion
Our results indicate that the skeletal benefit of PTX was attenuated in normocalcemic and normohormonal patients, suggesting that skeletal changes after PTX may depend on biochemical profile. 相似文献4.
Farah Deeba Manyou Ma Mehran Pesteie Jefferson Terry Denise Pugash Jennifer A. Hutcheon Chantal Mayer Septimiu Salcudean Robert Rohling 《Ultrasound in medicine & biology》2019,45(5):1081-1093
Attenuation coefficient estimation has the potential to be a useful tool for placental tissue characterization. A current challenge is the presence of inhomogeneities in biological tissue that result in a large variance in the attenuation coefficient estimate (ACE), restricting its clinical utility. In this work, we propose a new Attenuation Estimation Region Of Interest (AEROI) selection method for computing the ACE based on the (i) envelope signal-to-noise ratio deviation and (ii) coefficient of variation of the transmit pulse bandwidth. The method was first validated on a tissue-mimicking phantom, for which an 18%–21% reduction in the standard deviation of ACE and a 14%–24% reduction in the ACE error, expressed as a percentage of reported ACE, were obtained. A study on 59 post-delivery clinically normal placentas was then performed. The proposed AEROI selection method reduced the intra-subject standard deviation of ACE from 0.72 to 0.39 dB/cm/MHz. The measured ACE of 59 placentas was 0.77 ± 0.37 dB/cm/MHz, which establishes a baseline for future studies on placental tissue characterization. 相似文献
5.
Otavio Berwanger Renato D. Lopes Diogo D.F. Moia Francisco A. Fonseca Lixin Jiang Shaun G. Goodman Stephen J. Nicholls Alexander Parkhomenko Oleg Averkov Carlos Tajer Germán Malaga Jose F.K. Saraiva Helio P. Guimaraes Pedro G.M. de Barros e Silva Lucas P. Damiani Renato H.N. Santos Denise M. Paisani Tamiris A. Miranda Jose C. Nicolau 《Journal of the American College of Cardiology》2019,73(22):2819-2828
BackgroundThe efficacy of ticagrelor in the long-term post–ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain.ObjectivesThe purpose of this study was to evaluate the efficacy of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy.MethodsThis international, multicenter, randomized, open-label with blinded endpoint adjudication trial enrolled 3,799 patients (age <75 years) with STEMI receiving fibrinolytic therapy. Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300- to 600-mg loading dose, 75 mg daily thereafter). The key outcomes were cardiovascular mortality, myocardial infarction, or stroke, and the same composite outcome with the addition of severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events at 12 months.ResultsThe combined outcome of cardiovascular mortality, myocardial infarction, or stroke occurred in 129 of 1,913 patients (6.7%) receiving ticagrelor and in 137 of 1,886 patients (7.3%) receiving clopidogrel (hazard ratio: 0.93; 95% confidence interval: 0.73 to 1.18; p = 0.53). The composite of cardiovascular mortality, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events occurred in 153 of 1,913 patients (8.0%) treated with ticagrelor and in 171 of 1,886 patients (9.1%) receiving clopidogrel (hazard ratio: 0.88; 95% confidence interval: 0.71 to 1.09; p = 0.25). The rates of major, fatal, and intracranial bleeding were similar between the ticagrelor and clopidogrel groups.ConclusionAmong patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel. (Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis [TREAT]; NCT02298088) 相似文献
6.
7.
Janet Crane Jackie Manfredo Elisa Boscolo Mara Coyan Clifford Takemoto Maxim Itkin Denise M. Adams Timothy D. Le Cras 《Pediatric blood & cancer》2020,67(9)
Kaposiform lymphangiomatosis (KLA) is a rare, life‐threatening congenital lymphatic malformation. Diagnosis is often delayed due to complex indistinct symptoms. Blood angiopoietin‐2 (ANG2) levels are elevated in KLA and may be useful as a biomarker to monitor disease status. We report a 7‐year‐old male child with easy bruising, inguinal swelling, and consumptive coagulopathy, diagnosed with KLA. A multimodal treatment regimen of prednisone, sirolimus, vincristine, and adjunctive zoledronate was used. Plasma ANG2 levels were highly elevated at diagnosis but decreased during treatment. The patient showed significant clinical improvement over a 38‐month period and normalization of ANG2 levels correlated with resolution of the coagulopathy. 相似文献
8.
9.
10.
Rachel A. Katzenellenbogen Joseph J. Carter Joshua E. Stern Melinda S. Butsch Kovacic Parinda A. Mehta Sharon L. Sauter Denise A. Galloway Rachel L. Winer 《Clinical and Vaccine Immunology : CVI》2015,22(4):413-420
Persons with Fanconi anemia (FA) are at risk for human papillomavirus (HPV)-associated cancers; however, their natural HPV exposure and infection rates are unknown as is the adequacy with which they mount antibodies to HPV vaccination. This study aimed to determine, in 62 persons with FA, the seroprevalence of skin and mucosal HPV types, the seroprevalence in individuals self-reporting a history of HPV vaccination, and the factors associated with HPV seropositivity. A bead Luminex assay was used to determine seropositivity for HPV1, -2, and -4 (low-risk skin), -6 and -11 (low-risk mucosal, included in one HPV vaccine), -16 and -18 (high-risk mucosal, included in both HPV vaccines), and -52 and -58 (high-risk mucosal). Health- and behavior-related questionnaires were completed. Type-specific seroprevalence estimates and participant characteristics associated with seroprevalence were calculated; 48% reported HPV vaccination. Type-specific seropositivity in unvaccinated persons ranged from 7 to 21% for skin HPV types and 7 to 38% for mucosal HPV types. Among the unvaccinated participants, adults versus children demonstrated increased HPV1, -6, -16, and -58 seroprevalence of 45% versus 6%, 64% versus 22%, 64% versus 17%, and 36% versus 0%, respectively (all P < 0.05). The vaccinated participants versus the nonvaccinated participants demonstrated increased seroprevalence of HPV6, -11, -16, and -18 of 92% versus 38%, 92% versus 24%, 96% versus 34%, and 75% versus 7%, respectively (all P < 0.0001). Our data demonstrate that the unvaccinated participants had serologic evidence of prior skin and mucosal HPV infections and that seroprevalence increased among adults; in self-reported vaccinees, seroprevalence of HPV vaccine types was 75 to 96%. 相似文献